Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | SS-31 acts like a mechanic that specifically repairs the engine inside your cells (the mitochondria). By fixing the engines, it brings dead, tired cells back to life, reversing aging at the deepest possible level. | NAD+ is the raw fuel your cells use to stay alive. As we get older, our gas tank runs low, causing us to feel tired and age faster. Giving the body NAD+ refills the tank, turning back the clock on aging and energy. |
Studied For | Primary mitochondrial diseaseBarth syndrome (cardiolipin deficiency)Heart failure / ischemia-reperfusion injuryDry AMD (age-related macular degeneration)Mitochondrial agingCardiac energeticsSkeletal muscle mitochondriaKidney ischemia-reperfusion modelsROS reduction at mitochondriaCardiolipin stabilizationRespiratory chain Complex I-V efficiencyATP production enhancementFrailty / aging mitochondriaChronic kidney disease modelsNeurodegenerative disease mitochondriaExercise intolerance researchenergy productionanti-agingmitochondrial repairheart failurecognitive declineischemia reperfusionkidney protection | Aging / cellular senescenceMitochondrial / metabolic dysfunctionNeurodegeneration modelsSirtuin activation (SIRT1-7)DNA repair (PARP activation)Addiction / substance withdrawal researchChronic fatigue / energy restorationAlzheimer's and Parkinson's researchAlcohol use disorder detoxMetabolic syndromeInsulin resistanceCardiovascular disease modelsExercise performance and enduranceInflammation modulationNAD metabolism optimizationLongevity researchNAMPT upregulationCognitive enhancementDepression researchenergy productionanti-aginglongevitymitochondrial functionsirtuin activatoraddiction recoverybrain fog |
Research Areas | LongevityMitochondrial FunctionImmune | LongevityMetabolicMitochondrial FunctionCognitiveImmune |
Best Stacked With | nad-plusmots-cepithalonbac-water | ss-31mots-cepithalonglutathioneb125-amino-1mq |
Overview | ||
Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
Compound Class | Mitochondria-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2); cardiolipin-targeting | Essential coenzyme (dinucleotide); critical redox electron carrier in all living cells |
Molecular Target | Cardiolipin on inner mitochondrial membrane; scavenges mitochondrial ROS; stabilizes cristae architecture; restores respiratory chain efficiency | Sirtuin deacetylases (SIRT1-7); PARP1 for DNA repair; CD38/CD157 signaling; NADH/NAD+ redox balance in mitochondria |
Aliases / AKA | ElamipretideMTP-131BendaviaSS-31 peptideSzeto-Schiller 31D-Arg-dimethylTyr-Lys-Phe-NH2 | Nicotinamide adenine dinucleotideNADNAD+ coenzymeNAD plusBeta-nicotinamide adenine dinucleotideNAD IV therapy |
Parent Compound | Szeto-Schiller peptide series | Endogenous coenzyme |
Molecular Weight | 639.79 Da | 663.43 Da |
Amino Acid Sequence | D-Arg-Dmt-Lys-Phe-NH2 | dinucleotide |
CAS Number | 736992-21-5 | 53-84-9 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 457 Good | 85,150 Extensive |
Clinical Trials | Not Listed | 281281 Active |
Regulatory Status | FDA-approved (Sept 2025) for Barth syndrome; investigational elsewhere. | Not FDA-approved (compounded injectable); oral precursors sold as supplements. |
Evidence & Regulatory | ||
Half-Life | ~4 hours | ~2-4 hours |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | The Barth-syndrome trial (TAZPOWER) supported a 2025 FDA accelerated approval for Barth syndrome; the primary mitochondrial myopathy program (MMPOWER-3) failed its endpoints, and several cardiac and dry-AMD endpoints were mixed or not met. Still the strongest human evidence in this group. | Animal and precursor human studies support raising NAD+ for mitochondrial and sirtuin function. Direct injectable NAD+ human efficacy is sparse and uncontrolled; preliminary. |
Side Effects Noted | Injection-site reactions, headache, gastrointestinal symptoms; generally tolerable at studied doses. | Rapid IV infusion commonly causes chest tightness, flushing, nausea, and cramping that are rate-dependent and eased by slow infusion. Injection-site reactions for subcutaneous use. |
Warnings | The 2025 approval is narrow (Barth syndrome); other uses remain investigational. Research use only outside approved labeling. | Compounded injectable; not FDA-approved; parenteral pharmacokinetics are poorly characterized. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | sterile or bacteriostatic water | sterile water; dilute and infuse slowly for IV |
Storage Temp | cold, dark; avoid freeze-thaw | cold, dark, often -20C |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Non-natural residues improve stability. | Hygroscopic; reconstituted solution is unstable. |
Reconstituted Shelf Life | 28 Days Refrigerated | 7 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Two leading tissue-repair peptides with distinct healing mechanisms.
A systemic repair peptide versus a copper peptide for tissue and skin research.
A GHRH analog versus a selective ghrelin-receptor secretagogue on the GH axis.
A dual incretin agonist versus an amylin analog in metabolic research.
A triple incretin agonist versus an amylin analog in weight research.
Two metabolic research compounds targeting mitochondrial and NNMT pathways.
NAD+ metabolism versus a mitochondrial-derived peptide in longevity research.
Two copper research peptides studied for skin and hair.
A long-acting versus a short-acting GHRH analog.
A selective versus a first-generation ghrelin-receptor secretagogue.
A GLP-1 agonist versus a GLP-1/amylin combination in metabolic research.
Two peptides studied for gut and mucosal repair.
Melanocortin versus oxytocin pathways in intimacy and libido research.
Two thymic immune-modulating research peptides.
An anxiolytic nootropic versus a sleep-associated research peptide.
Direct IGF-1 signaling versus myostatin inhibition in muscle research.
A mitochondrial-targeted peptide versus NAD+ in cellular-energy research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
